< Back to previous page
Researcher
Peter Carmeliet
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Cardiac and vascular medicine
- See also: Peter Carmeliet (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Carmeliet Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → 30 Sep 2005
Projects
31 - 40 of 110
- Metabolic characterisation of renal endothelial cells in health and diseasesFrom21 Feb 2018 → 31 Oct 2023Funding: FWO fellowships
- Pathological vessel remodeling in liver disease: a single cell transcriptome study to identify new targetsFrom1 Feb 2018 → 9 Oct 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
- DE ROL VAN HET ENDOTHEEL IN MUCOVISCIDOSE GEASSOCIEERDE LEVERZIEKTEFrom1 Dec 2017 → 24 Nov 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- Preclinical concept validation of tumor endothelial cell metabolism for novel anti-angiogenic therapyFrom1 Nov 2017 → 31 Oct 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Single cell analysis of tumor endothelial cell genomic and transcriptomic heterogeneityFrom1 Oct 2017 → 30 Sep 2020Funding: FWO fellowships
- Improving immunotherapy via tumor vessel normalization by blocking endothelial cell glycolysisFrom1 Jan 2017 → 31 Dec 2020Funding: Foundations, funds and other with scientific goal
- Tumor vessel normalization by targeting endothelial cell metabolism: a novel strategy to improve combination chemo/immuno-therapies against cancer.From1 Jan 2017 → 31 Dec 2020Funding: Nonprofit institution or equivalents
- Tumor vessel co-option at single-cell resolutionFrom1 Nov 2016 → 31 May 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- How to age and stay fit: uncovering and understanding metabolic (mal)adaptations driving aging in endothelial cellsFrom1 Oct 2016 → 30 Sep 2020Funding: FWO fellowships
- A multidisciplinary approach using global metabolomics, genomescale metabolic modelling, shRNA screen and biological validation to discover novel pro-angiogenic metabolic targets.From1 Oct 2016 → 14 Feb 2017Funding: FWO fellowships
Publications
1 - 10 of 587
- Fatty acid oxidation fuels natural killer cell responses against infection and cancer.(2024)
Authors: Peter Carmeliet
Pages: e231925412 - Targeting hypoxia-inducible factors: therapeutic opportunities and challenges(2024)
Authors: Peter Carmeliet
- Editorial Expression of Concern: The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system.(2024)
Authors: Peter Carmeliet
Pages: E12 - The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression (vol 23, pg 1476, 2018)(2023)
Authors: Peter Carmeliet
- Detailed protocol for a corneal thermal cauterization-based (lymph-)angiogenesis assay in mice(2023)
Authors: Anh-Co Truong, Koen Veys, Mieke Dewerchin, Peter Carmeliet
- Glucose Controls Glucagon Secretion by Regulating Fatty Acid Oxidation in Pancreatic α-Cells(2023)
Authors: Peter Carmeliet
Pages: 1446 - 1459 - Renal Endothelial Cell Metabolism in Health and Acute Kidney Injury: a window for therapeutic opportunities(2023)
Authors: Mila Borri, Peter Carmeliet, Guy Eelen, Sébastien Dumas
- VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway(2023)
Authors: Mieke Dewerchin, Peter Carmeliet
- PARTIAL MYELOID INHIBITION OF KEY GLYCOLYTIC ENZYME PFKFB3 INCREASES HEPATIC STEATOSIS AND INFLAMMATION, BUT DOES NOT AFFECT ATHEROSCLEROSIS(2023)
Authors: Peter Carmeliet
- Understanding tumour endothelial cell heterogeneity and function from single-cell omics(2023)
Authors: Peter Carmeliet
Pages: 544 - 564
Patents
1 - 10 of 10
- Carnitine palmitoyltransferase 1 inhibitors for inhibition of pathological angiogenesis (Inventor)
- Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor (Inventor)
- Inhibition of plgf to treat philadelphia chromosome positive leukemia (Inventor)
- Means and methods for treating lung hypoplasia (Inventor)
- Use of VEGF and homologues to treat neuron disorders (Inventor)
- Novel anti-PLGF antibody (Inventor)
- Anti-angiogenic therapy (Inventor)
- Responsiveness to angiogenesis inhibitors (Inventor)
- CARNITINE PALMITOYLTRANSFERASE 1 INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)
- GLUTAMINE SYNTHETASE INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)